Rapid Growth of Human Rabies Vaccines Market 2020 | Top Key Companies (GSK, Sanofi, Novartis, Cadila Pharma, Merck, Wyeth Pharma, Medimmune) | Forecasts till 2025

All information provided in the report is derived from trusted industrial sources. Global Human Rabies Vaccines Market research reports finds market figures between 2020 and 2025. The market will exhibit remarkable CAGRs in the aforementioned period.

Global Human Rabies Vaccines Market Overview:

The Global Human Rabies Vaccines Market research report is the investigation arranged by investigators, which contain a point by point examination of drivers, limitations, and openings alongside their effect on the Human Rabies Vaccines Market development (2020 - 2025).

The significant key factors driving the growth of the Global Human Rabies Vaccines Market are rising global incidences of mortality due to rabies, increasing issue of stray dogs in countries with low economic development, growing number of pets, lack of pet management services, low immunization rates in pets, and rising friendliness with pets. As per the WHO, around 99% of rabies cases reported in 2015 were from domestic dogs. Other animals leading to rabies infection can be wild dogs, bats, foxes, raccoons, cats, and skunks. Bites, contact with saliva, and scratches by these animals are considered as the main causes of rabies infection.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273368 .

The Global Human Rabies Vaccines Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global Human Rabies Vaccines Market is sub-segmented into Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine and others. On the basis of Application, the Global Human Rabies Vaccines Market is classified into Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis and others.

In terms of the geographic analysis, The Human Rabies Vaccines Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Human Rabies Vaccines Market ecosystem results in the increasing adoption of these systems in North America.

Global Medical Industry News:

GlaxoSmithKline (GSK) (June 29, 2020) - GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease - GlaxoSmithKline plc today announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anaemia due to chronic kidney disease (CKD).

Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “The approval of Duvroq brings a new, convenient oral treatment option to nearly 3.5 million patients in Japan who have anaemia associated with renal disease. We are pleased with this first approval and look forward to sharing data from our ongoing phase III programme as we seek to help many more patients suffering with this disease around the world.”

Anaemia is common in patients with CKD because the kidneys no longer produce adequate amounts of erythropoietin, a hormone involved in prompting the production of red blood cells. HIF-PHIs are a new class of drug that trigger the body’s adaptations to hypoxia (i.e. oxygen deprivation) and encourages the bone marrow to make more red blood cells and so reduce anaemia, thereby benefitting patients.

The JNDA was primarily based on positive data from the phase III programme conducted in Japan. The studies evaluated Duvroq for the treatment of anaemia in patients across the spectrum of CKD from stages 3-5. This included patients on dialysis, including both hemo- and peritoneal dialysis, and those not on dialysis, regardless of prior anaemia treatment with erythropoiesis-stimulating agents (ESAs). In contrast to current standard of care in patients with CKD which requires injections, Duvroq offers convenience with oral administration and flexibility with once-daily dosing for dialysis and non-dialysis patients.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Human Rabies Vaccines Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273368/single .

Top Leading Key in Players Global Human Rabies Vaccines Market: Sanofi Pasteur, Novartis Vaccines and Diagnostics, Cadila Pharmaceuticals, GlaxoSmithKline Biologicals, Merck, Wyeth pharmaceuticals, Berna Biotech, Medimmune and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

With the presence of a large pool of participants, the Global Human Rabies Vaccines Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). Sanofi Pasteur, Novartis Vaccines and Diagnostics, Cadila Pharmaceuticals, GlaxoSmithKline Biologicals, Merck, Wyeth pharmaceuticals, Berna Biotech, Medimmune are some of the key vendors of Human Rabies Vaccines across the world. These players across Human Rabies Vaccines Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.

Region segment: Human Rabies Vaccines Market report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Human Rabies Vaccines in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273368 .

Major Points in Table of Contents:

Global Human Rabies Vaccines Market Report 2020

1 Human Rabies Vaccines Product Definition

2 Global Human Rabies Vaccines Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Human Rabies Vaccines Shipments

2.2 Global Manufacturer Human Rabies Vaccines Business Revenue

2.3 Global Human Rabies Vaccines Market Overview

2.4 COVID-19 Impact on Human Rabies Vaccines Industry

3 Manufacturer Human Rabies Vaccines Business Introduction

3.1 Sanofi Pasteur?Inc. Human Rabies Vaccines Business Introduction

3.2 Novartis Vaccines and Diagnostics Ltd. Human Rabies Vaccines Business Introduction

3.3 Cadila Pharmaceuticals Ltd. Human Rabies Vaccines Business Introduction

3.4 GlaxoSmithKline Biologicals Human Rabies Vaccines Business Introduction

3.5 Merck?Co Inc. Human Rabies Vaccines Business Introduction

3.6 Wyeth pharmaceuticals Human Rabies Vaccines Business Introduction

………………. Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.